Diseases associated with ageing are among the critical problems of society. The European population will be the oldest in the world in 2030. The project will develop new laboratory procedures, microfluid chips, biomaterials and biopharmaceuticals for prevention, diagnosis and treatment of cerebrovascular and neurodegenerative diseases. Experts in molecular/cell biology, immunology and protein chemistry with clinical neurology and product development by leading Czech biotechnology companies will be combined.